p21 and p53 immunostaining and survival following systemic chemotherapy for urothelial cancer

Urologia Internationalis

Volumn 69, Issue 3, 2002, Pages 174-180

  Jankevicius, Feliksas ^a   Goebell, Peter ^a   Kushima, Mayumi ^a   Schulz, Wolfgang A ^a   Ackermann, Rolf ^a   Schmitz Dräger, Bernd J ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Euromed Clinic   (Germany)

Author keywords

Chemotherapy; p21; p53; Transitional cell carcinoma, survival

Indexed keywords

CISPLATIN; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTECTOMY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATOR GENE; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; UROGENITAL TRACT TUMOR;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; ONCOGENE PROTEIN P21(RAS); PROBABILITY; PROGNOSIS; REGISTRIES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0036419176     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000063949     Document Type: Article

References (35)

1. Geller NL, Sternberg CN, Pennenberg D, Scher H, Yagoda A: Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 1991;67:1525-1531.
2. Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1992;10:1066-1073.
3. Igawa M, Kadena K, Ueda M, Usui T: Association between patient characteristics and treatment history, and toxicity associated with methotrexate, vinblastine, Adriamycin and cisplatin (M-VAC) for advanced urothelial cancer. Br J Urol 1994;73:263-267.
4. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1994;74: 957-967.
5. Junker K, Wiethege T, Müller KM, Thomas M: p53 tumour-suppressor gene in non-small cell lung cancer with neoadjuvant therapy. J Cancer Res Clin Oncol 2000;126:238-245.
6. Cascinu S, Catalano V, Aschele C, Barni S, Debernardis D, Gallo L, Bandelloni R, Staciolli MP, Baldelli AM, Brenna A, Valenti A, Murretto P, Catalano G: Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucoverin combination. Ann Oncol 2000;11:1053-1056.
7. Stal O, Stenmark-Askmalm M, Wingren S, Rutqvist LE, Skoog L, Ferraud L, Sullivan S, Carstensen J, Nordenskjöld B: p53 expression and the results of adjuvant therapy of breast cancer. Acta Oncol 1995;34:767-770.
8. Lipponen PK: Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 1993;53: 365-370.
9. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA, Cote RJ: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-1264.
10. Kuczyk MA, Bokemeyer C, Serth J, Hervatin C, Oelke M, Höfner K, Tan HK, Jonas U: p53 overexpression as a prognostic factor for advanced stage bladder cancer (abstract). Eur J Cancer 1995;31:2243-2247.
11. Sarkis AS, Bajorin DF, Reuter VE, Herr HW, Netto G, Zhang ZF, Schultz PK, Cordon-Cardo C, Scher HI: Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995;13:1384-1390.
12. Qureshi KN, Griffiths TR, Robinson MC, March C, Roberts JT, Hall RR, Lunec J, Neal DE: TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer. Clin Cancer Res 1999;5:3500-3507.
13. Hartwell LH, Kastan MB: Cell cycle control and cancer. Science 1994;266:1821-1828.
14. Waldman F, Kinzler K, Vogelstein B: p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995;55:5187-5190.
15. Dulic V, Kaufman WK, Wilson SJ, Tisty TD, Lees E, Harper JW, Elledge SJ, Reed SI: p53-dependent inhibition of cycline-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994;76:1014-1024.
16. Sarkar S, Julicher KP, Burger MS, Della Valle V, Larsen CJ, Yeager TR, Grossman TB, Nickels RW, Protzel C, Jarrard DF, Reznikoff CA: Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers. Cancer Res 2000;60:3862-3871.
17. Sin LH, Wittekind C (eds): TNM Classification of Malignant Tumours, Ed 5. New York, Wiley-Liss, 1997.
18. Mostofi FK, Sobin LH, Torlini H: Histological typing of urinary bladder tumors; in: International Histological Classification of Tumors. Geneva, World Health Organization, 1973, No 10.
19. Cordon-Cardo C, Dalbagni G, Saez GT, Oliver MR, Zhang ZF, Rosai J, Reuter VE, Pellicer A: p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns. Int J Cancer 1994;56:347-353.
20. Clasen S, Schulz WA, Gerharz CD, Grimm MO, Christoph F, Schmitz-Dräger BJ: Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma. Br J Cancer 1998;77:515-521.
21. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
22. Kerr JFR, Winterford CM, Harmon BV: Apoptosis: Its significance in cancer and cancer therapy. Cancer 1994;73:2013-2026.
23. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-1327.
24. Waldman T, Zhang Y, Dillehay L, Kinzler K, Vogelstein B, Williams J: Cell cycle arrest versus cell death in cancer therapy. Nat Med 1997; 9:1034-1036.
25. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-825.
26. Waldman T, Lengauer C, Kinzler KW, Vogel-stein B: Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996;381:713-716.
27. Bukholm I, Nesland J, Käresen R, Jacobsen U, Borresen AL: Relationship between abnormal p53 protein and failure to express p21. J Pathol 1997;181:140-145.
28. Zhang W, Grasso L, McClain CD, Gambel AM, Cha Y, Travali S, Deisseroth AB, Mercer E: p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 1995;55: 668-674.
29. Jakus J, Yeudall AW: Growth inhibitory concentrations of EGF induce p21 (WAF1/CIP1) and alter cell cycle control in squamous carcinoma cells. Oncogene 1996;12:2369-2376.
30. Jahnson S, Karlsson MG: Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma. Cancer 2000;89:619-629.
31. Stein JP, Ginsberg DA, Grossfeld GD, Esrig D, Freeman J, Dickinson MG, Groshen S, Nichols PA, Jones PA, Skinner DG, Cote RJ: The effect of p21 expression on tumor progression in p53 altered bladder cancer (abstract). J Urol 1996; 155(suppl):628.
32. WAF1/CIP1 mutations in superficial and invasive transitional cell carcinomas. Oncogene 1996;13:1831-1837.
33. Peng HQ, Hogg D, Malkin D: Mutations of p53 gene do not occur in testis cancer. Cancer Res 1993;53:3574-3579.
34. Koga F, Kitahara S, Arai K, Honda M, Sumi S, Yoshida K: Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer. Jpn J Cancer Res 2000; 91:416-423.
35. Schultz PK, Herr HW, Zhang ZF, Bajorin DF, Seidman A, Sarkis A, fair WR, Scherr D, Bosl GJ, Scher HI: Neoadjuvant chemotherapy for invasive bladder cancer: Prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol 1994;12:1394-1401.